Genmab goes on the offensive in Janssen daratumumab dispute

Danish biotech Genmab (Nasdaq: GMAB) has started new legal proceedings against Janssen relating to their license agreement for daratumumab, just a couple of months after losing a previous dispute with the Johnson & Johnson (NYSE: JNJ) subsidiary over the same drug.

As part of the prior arbitration, the tribunal ruled in favor of Janssen on the question as to whether Genmab is required to share in royalty payments to Halozyme Therapeutics (Nasdaq: HALO) for its technology used in the subcutaneous formulation of daratumumab, which is marketed in the USA as Darzalex Faspro.

The tribunal based its ruling on the finding that Darzalex Faspro constitutes a new licensed product under the license agreement.